Chapter 21 Disease-Modifying Therapies in Motor Neuron Disorders: The Present Position and Potential Future Developments

Blue Books of Practical Neurology

Volumn 28, Issue C, 2003, Pages 497-544

  Turner, Martin R ^a   Leigh, P Nigel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33544469983     PISSN: 18773419     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-3419(09)70122-9     Document Type: Article

References (376)

1. Charcot J.M. Sclerose des cordons lateraux de la moelle epiniere chez une femme hysterique atteinte de contracture permanente des quatre membres. Bull Soc Med Hopit Paris (1865) 24-35
2. Turner M.R., Parton M.J., and Leigh P.N. Clinical trials in ALS: an overview. Semin Neurol 21 (2001) 167-175
3. Brooks B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 124 suppl (1994) 96-107
4. Miller R.G., Munsat T.L., Swash M., and Brooks B.R. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology Committee on Research. J Neurol Sci 169 (1999) 2-12
5. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House "Therapeutic Trials in ALS" Workshop Contributors. J Neurol Sci 129 suppl (1995) 1-10
6. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial Revisited: Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis (1998), World Federation of Neurology, London, UK. http://www.wfnals.org/guidelines/1998elescorial/elescorial1998.htm Available at: www.wfnals.org/guidelines/1998elescorial/elescorial1998.htm.
7. Leigh P.N., Simmons A., Williams S.C.R., et al. Imaging: MRS/MRI/PET/SPECT: Summary. Amyotroph Lateral Scler Other Motor Neuron Disord 3 suppl 1 (2002) S75-S80
8. Cedarbaum J.M., Stambler N., Malta E., et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169 (1999) 13-21
9. 1H-MRS) in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 1 suppl 2 (2000) S7-S16
10. Turner M.R., and Leigh P.N. Positron emission tomography (PET)-its potential to provide surrogate markers in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 1 suppl 2 (2000) S17-S22
11. Mills K.R. Motor neuron disease. Studies of the corticospinal excitation of single motor neurons by magnetic brain stimulation. Brain 118 pt 4 (1995) 971-982
12. Goldstein L.H., Atkins L., and Leigh P.N. Correlates of quality of life in people with motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 3 (2002) 123-129
13. Hickey A.M., Bury G., O'Boyle C.A., et al. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. BMJ 313 (1996) 29-33
14. Bergner M., Bobbitt R.A., Carter W.B., and Gilson B.S. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19 (1981) 787-805
15. Andres P.L., Hedlund W., Finison L., et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 36 (1986) 937-941
16. Lacomblez L., Bensimon G., Leigh P.N., et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347 (1996) 1425-1431
17. Guiloff R.J., Goonetilleke A., and Emami J. Riluzole and amyotrophic lateral sclerosis. Lancet 348 (1996) 336-337
18. Eisen A., and Krieger C. ALS Therapy, Therapeutic Trials, and Neuroprotection. Amyotrophic Lateral Sclerosis-A Synthesis of Research and Clinical Practice (1998), Cambridge University Press 209-237
19. Pinto A.C., Evangelista T., Carvalho M., et al. Respiratory assistance with a non-invasive ventilator (BiPAP) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 129 suppl (1995) 19-26
20. Aboussouan L.S., Khan S.U., Banerjee M., et al. Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve 24 (2001) 403-409
21. Lyall R.A., Donaldson N., Polkey M.I., et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 124 pt 10 (2001) 2000-2013
22. Armon C. How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?. ALS and other motor neuron disorders 1 (1999) 3-14
23. Brooks B.R., Sanjak M., Belden D., and Waclawik A. Motor Neurone Disease: Basic Designs, Sample Sizes and Pitfalls. In: Guiloff R.J. (Ed). Clinical Trials in Neurology (2001), Springer, New York 427-450
24. Miller R.G. Measurement of strength: summary. Amyotroph Lateral Scler Other Motor Neuron Disord 3 suppl 1 (2002) S51-S53
25. Sorenson E. Measurement of strength: Con. Amyotroph Lateral Scler Other Motor Neuron Disord 3 suppl 1 (2002) S49-S50
26. Andres P.L., Finison L.J., Conlon T., et al. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 38 (1988) 405-408
27. Andres P.L., Skerry L.M., Thornell B., et al. A comparison of three measures of disease progression in ALS. J Neurol Sci 139 suppl (1996) 64-70
28. Haverkamp L.J., Appel V., and Appel S.H. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118 pt 3 (1995) 707-719
29. Bourke S.C., Shaw P.J., and Gibson G.J. Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS. Neurology 57 (2001) 2040-2044
30. Lyall R.A., Donaldson N., Fleming T., et al. A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 57 (2001) 153-156
31. Fitting J.W., Paillex R., Hirt L., et al. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 46 (1999) 887-893
32. Norris Jr. F.H., Calanchini P.R., Fallat R.J., et al. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 24 (1974) 721-728
33. Appel V., Stewart S.S., Smith G., and Appel S.H. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 22 (1987) 328-333
34. Lai E.C., Felice K.J., Festoff B.W., et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49 (1997) 1621-1630
35. Borasio G.D., Robberecht W., Leigh P.N., et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51 (1998) 583-586
36. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol 53 (1996) 141-147
37. Meininger V., and Salachas F. Review of Clinical Trials. In: Meininger V., Swash M., and Brown Jr. R.H. (Eds). Amyotrophic Lateral Sclerosis (2000), Martin Dunitz, London 389-402
38. Iwasaki Y., Ikeda K., Ichikawa Y., et al. The diagnostic interval in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 104 (2002) 87-89
39. Turner M., and Al Chalabi A. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59 (2002) 2012-2013
40. Turner M.R., Bakker M., Sham P., et al. Prognostic modeling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 3 (2002) 15-21
41. Simmons Z., Bremer B.A., Robbins R.A., et al. Quality of life in ALS depends on factors other than strength and physical function. Neurology 55 (2000) 388-392
42. Jenkinson C., Fitzpatrick R., Swash M., and Peto V. The ALS Health Profile Study: quality of life of amyotrophic lateral sclerosis patients and carers in Europe. J Neurol 247 (2000) 835-840
43. Jenkinson C. Quality of life in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) 223-224
44. Coulthard-Morris L., Burks J.S., and Herndon R.M. Rehabilitation Outcome Measures. In: Herndon R.M. (Ed). Handbook of Neurologic Rating Scales (1997), Demos Vermande, New York 225-264
45. Neudert C., Wasner M., and Borasio G.D. Patients' assessment of quality of life instruments: a randomized study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis. J Neurol Sci 191 (2001) 103-109
46. Bromberg M.B., Anderson F., Davidson M., and Miller R.G. Assessing health status quality of life in ALS: comparison of the SIP/ALS-19 with the ALS Functional Rating Scale and the Short Form-12 Health Survey. ALS C.A.R.E. Study Group. Clinical Assessement, Research, and Education. Amyotroph Lateral Scler Other Motor Neuron Disord 2 (2001) 31-37
47. McGuire D., Garrison L., Armon C., et al. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group. Neurology 46 (1996) 1442-1444
48. McGuire D., Garrison L., Armon C., et al. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group. J Neurol Sci 152 suppl 1 (1997) S18-S22
49. Jenkinson C., Fitzpatrick R., Brennan C., et al. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol 246 suppl 3 (1999) III16-III21
50. Jenkinson C., Fitzpatrick R., Brennan C., and Swash M. Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSQ-40. Amytroph Lateral Scler Other Motor Neuron Disord 1 (1999) 33-40
51. Jenkinson C., Levvy G., Fitzpatrick R., and Garratt A. The amyotrophic lateral sclerosis assessment questionnaire (ALSAQ-40): tests of data quality, score reliability and response rate in a survey of patients. J Neurol Sci 180 (2000) 94-100
52. Jenkinson C., and Fitzpatrick R. Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry 70 (2001) 70-73
53. Bromberg M.B., and Forshew D.A. Comparison of instruments addressing quality of life in patients with ALS and their caregivers. Neurology 58 (2002) 320-322
54. Al-Chalabi A., and Leigh P.N. Recent advances in amyotrophic lateral sclerosis. Curr Opin Neurol 13 (2000) 397-405
55. Shaw C.E., Al Chalabi A., and Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 1 (2001) 69-76
56. Rowland L.P., and Shneider N.A. Amyotrophic lateral sclerosis. N Engl J Med 344 (2001) 1688-1700
57. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2 (2001) 806-819
58. Morrison K.E. Therapies in amyotrophic lateral sclerosis-beyond riluzole. Curr Opin Pharmacol 2 (2002) 302-309
59. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81 (1999) 163-221
60. Leigh P.N., and Meldrum B.S. Excitotoxicity in ALS. Neurology 47 6, suppl 4 (1996) S221-S227
61. Heath P.R., and Shaw P.J. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26 (2002) 438-458
62. Plaitakis A., and Caroscio J.T. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 22 (1987) 575-579
63. Rothstein J.D., Tsai G., Kuncl R.W., et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28 (1990) 18-25
64. Shaw P.J., Forrest V., Ince P.G., et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 4 (1995) 209-216
65. Spreux-Varoquaux O., Bensimon G., Lacomblez L., et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 193 (2002) 73-78
66. Maragakis N.J., and Rothstein J.D. Glutamate transporters in neurologic disease. Arch Neurol 58 (2001) 365-370
67. Rothstein J.D., Van Kammen M., Levey A.I., et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38 (1995) 73-84
68. Howland D.S., Liu J., She Y., et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 99 (2002) 1604-1609
69. Lin C.L., Bristol L.A., Jin L., et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20 (1998) 589-602
70. Meyer T., Fromm A., Munch C., et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci 170 (1999) 45-50
71. Flowers J.M., Powell J.F., Leigh P.N., et al. Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Ann Neurol 49 (2001) 643-649
72. Askmark H., Aquilonius S.M., Gillberg P.G., et al. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 56 (1993) 197-200
73. Plaitakis A., Smith J., Mandeli J., and Yahr M.D. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet 1 (1988) 1015-1018
74. Testa D., Caraceni T., and Fetoni V. Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol 236 (1989) 445-447
75. Gil R., Neau J.P., et al. A double-blind placebo-controlled study of branched chain amino acids and l-threonine for the short-term treatment of signs and symptoms of amyotrophic lateral sclerosis. La Semaine des Hôpitaux (Paris) 68 (1992) 1472-1475
76. Plaitakis A., Sivak M., et al. Treatment of amyotrophic lateral sclerosis with branched chain amino acids (BCAA): results of a second study. Neurology 42 suppl 3 (1992) 454
77. The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure?. Neurology 43 (1993) 2466-2470
78. Steiner T.J. Multinational trial of branched-chain amino acids in amyotrophic lateral sclerosis. Muscle Nerve suppl 1 (1994) S166
79. Tandan R., Bromberg M.B., Forshew D., et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis, I: clinical, functional, and maximum isometric torque data. Neurology 47 (1996) 1220-1226
80. Amino Acids for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) (Protocol for a Cochrane Review) (2002), Update Software, Oxford
81. Patten B.M., and Klein L.M. l-Threonine and the modification of ALS. Neurology 38 suppl 1 (1988) 354-355
82. Blin O., Serratrice G., Pouget J., et al. Short-term double-blind vs placebo trial of l-threonine in amyotrophic lateral sclerosis [in French]. Presse Med 18 (1989) 1469-1470
83. Blin O., Pouget J., Aubrespy G., et al. A double-blind placebo-controlled trial of l-threonine in amyotrophic lateral sclerosis. J Neurol 239 (1992) 79-81
84. Hugon J., and Preux P.M. Glycine and l-threonine therapeutic trials in amyotrophic lateral sclerosis (ALS). Neurology 42 suppl 3 (1992) 454
85. Testa D., Caraceni T., Fetoni V., and Girotti F. Chronic treatment with l-threonine in amyotrophic lateral sclerosis: a pilot study. Clin Neurol Neurosurg 94 (1992) 7-9
86. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 47 6, suppl 4 (1996) S233-S241
87. Schiefer J., Landwehrmeyer G.B., Luesse H.G., et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov Disord 17 (2002) 748-757
88. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330 (1994) 585-591
89. Riviere M., Meininger V., Zeisser P., and Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 55 (1998) 526-528
90. Miller R.G., Mitchell J.D., Lyon M., and Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2002) CD001447.
91. Meininger V, Lacomblez L, Bensimon G. Unpublished report: Controlled Trial of Riluzole in Patients with Advanced ALS. RP 54272-302 1995. 1995.
92. Yanagisawa N., Tashirao K., Tohgi H., et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo controlled study in Japan. Igakuno Ayumi 182 (1997) 851-866
93. Sojka P., Andersen P.M., and Forsgren L. Effects of riluzole on symptom progression in amyotrophic lateral sclerosis. Lancet 349 (1997) 176-177
94. Kalra S., Cashman N.R., Genge A., and Arnold D.L. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9 (1998) 1757-1761
95. Pongratz D., Neundorfer B., and Fischer W. German open label trial of riluzole 50mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS). J Neurol Sci 180 (2000) 82-85
96. Desiato M.T., Palmieri M.G., Giacomini P., et al. The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation. J Neurol Sci 169 (1999) 98-107
97. Arriada-Mendicoa N., Otero-Siliceo E., Burbano G., and Corona-Vazquez T. Open label study of riluzole for the treatment of amyotrophic lateral sclerosis. Revista Ecuatoriana Neurol 8 (1999) 33-36
98. Couratier P., Druet-Cabanac M., Truong C.T., et al. Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS [in French]. Rev Neurol (Paris) 156 (2000) 357-363
99. Brooks B.R., Belden D.S., Roelke K., et al. Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiologic study. Amyotroph Lateral Scler Other Motor Neuron Disord 2 suppl 2 (2001) 60-61
100. Traynor B.J., Alexander M., Corr B., et al. An outcome study of riluzole in amyotrophic lateral sclerosis. A population-based study in Ireland 1996-2000. J Neurol 250 (2003) 473-479
101. Debove C., Zeisser P., Salzman P.M., et al. The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2 (2001) 153-158
102. Lacomblez L., Bensimon G., Leigh P.N., et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 3 (2002) 23-29
103. Bensimon G., Lacomblez L., Delumeau J.C., et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 249 (2002) 609-615
104. Ludolph A.C., and Riepe M.W. Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against. Neurology 53 8, suppl 5 (1999) S46-S49
105. Meininger V., Lacomblez L., and Salachas F. What has changed with riluzole?. J Neurol 246 suppl 6 (2000) 19-22
106. Chio A., Mora G., Leone M., et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59 (2002) 99-103
107. Armon C., Guiloff R.J., and Bedlack R. Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold. Amyotroph Lateral Scler Other Motor Neuron Disord 3 (2002) 109-112
108. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 49 (1997) 657-659
109. Booth-Clibborn N, Best L, Stein K Riluzole for motor neurone disease. In L Best, R Milne, K Stein (eds), The Wessex Institute for Health Research & Development. Development & Evaluation Committee Report. 1997; 73: 1-21.
110. Ginsberg G.M., and Lev B. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis. Pharmacoeconomics 12 (1997) 578-584
111. Gray A.M. ALS/MND and the perspective of health economics. J Neurol Sci 160 suppl 1 (1998) S2-S5
112. Chilcott J, Golightly P, Jefferson D, et al. The Use of Riluzole in the Treatment of Amyotrophic Lateral Sclerosis (Motor Neurone Disease). Sheffield: Trent Institute for Health Services Research, University of Leicester, Nottingham and Sheffield, 1997; 1-37.
113. Munsat T.M., Riviere M., Swash M., and Leclerc C. Economic burden of amyotrophic lateral sclerosis in the United Kingdom. J Med Econ 1 (1998) 235-245
114. Messori A., Trippoli S., Becagli P., and Zaccara G. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci. Pharmacoeconomics 16 (1999) 153-163
115. Tavakoli M., Davies H., and Malek M. Modelling the long-term cost-effectiveness of riluzole for the treatment of amyotrophic lateral sclerosis. J Med Econ 2 (1999) 1-14
116. Tavakoli M., and Malek M. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. J Neurol Sci 191 (2001) 95-102
117. Kiebert G.M., Green C., Murphy C., et al. Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci 191 (2001) 87-93
118. National Institute of Clinical Excellence. Guidance on the Use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease. National Institute of Clinical Excellence, 2001.
119. Bryan S, Barton P, Burls A. The Clinical Effectiveness and Cost-Effectiveness of Riluzole for Motor Neurone Disease-An Update. West Midland Development and Evaluation Service, Full Document and Summary of Evidence Submitted to NICE. Update Assessment Report. 2000.
120. Leigh N. NICE recommends riluzole for the treatment of ALS. Adv Clin Neurosci Rehabil 1 (2001) 9-12
121. Eisen A., Stewart H., Schulzer M., and Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 20 (1993) 297-301
122. Miller R.G., Moore D., Young L.A., et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 47 (1996) 1383-1388
123. McDermott M.P., and Rowland L.P. ALS defeats gabapentin: reflections on another failed treatment. Neurology 56 (2001) 826-827
124. Simpson E.P., Mosier D., and Appel S.H. Mechanisms of disease pathogenesis in amyotrophic lateral sclerosis. A central role for calcium. Adv Neurol 88 (2002) 1-19
125. Miller R.G., Smith S.A., Murphy J.R., et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 19 (1996) 511-515
126. Miller R.G., Shepherd R., Dao H., et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromusc Disord 6 (1996) 101-104
127. Szczudlik A., Tomik B., Slowik A., and Kasprzyk K. Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes [in Polish]. Neurol Neurochir Pol 32 (1998) 821-829
128. Canton T., Bohme G.A., Boireau A., et al. RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J Pharmacol Exp Ther 299 (2001) 314-322
129. Jain K.K. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 9 (2000) 1397-1406
130. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767
131. Tateishi N., Mori T., Kagamiishi Y., et al. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 22 (2002) 723-734
132. Provinciali L., Giovagnoli A.R., Di Bella P., et al. A therapeutic trial of thymic factor in amyotrophic lateral sclerosis (ALS). Adv Exp Med Biol 209 (1987) 293-296
133. Bunina T.L., Khondkarian O.A., Korshunova T.S., et al. Treatment of amyotrophic lateral sclerosis with ribonucleotides [in Russian]. Zh Nevropatol Psikhiatr Im S S Korsakova 76 (1976) 166-174
134. Majkowski J. Long-term treatment of amyotrophic lateral sclerosis with phthalazinol. Adv Second Messenger Phosphoprotein Res 25 (1992) 409-416
135. Smith R.A., Melmed S., Sherman B., et al. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 16 (1993) 624-633
136. Engel W.K., Siddique T., and Nicoloff J.T. Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. Lancet 2 (1983) 73-75
137. Imoto K., Saida K., Iwamura K., et al. Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone. J Neurol Neurosurg Psychiatry 47 (1984) 1332-1334
138. Braun S.R., Sufit R.L., and Brooks B.R. Pulmonary effects of thyrotropin-releasing hormone in amyotrophic lateral sclerosis. Lancet 2 (1984) 529-530
139. Stober T., Schimrigk K., Dietzsch S., and Thielen T. Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis. J Neurol 232 (1985) 13-14
140. Serratrice G., Desnuelle C., Guelton C., et al. Trial of thyrotropin-releasing factor in amyotrophic lateral sclerosis [in French]. Presse Med 14 (1985) 487-488
141. Caroscio J.T., Cohen J.A., Zawodniak J., et al. A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Neurology 36 (1986) 141-145
142. Brooke M.H., Florence J.M., Heller S.L., et al. Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Neurology 36 (1986) 146-151
143. Mitsumoto H., Salgado E.D., Negroski D., et al. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 36 (1986) 152-159
144. Serratrice G., Desnuelle C., Crevat A., et al. Treatment of amyotrophic lateral sclerosis with thyrotropin releasing hormone [in French]. Rev Neurol (Paris) 142 (1986) 133-139
145. Yamane K., Osawa M., Kobayashi I., and Maruyama S. Treatment of amyotrophic lateral sclerosis with thyrotropin-releasing hormone (TRH). Jpn J Psychiatry Neurol 40 (1986) 179-187
146. Formisano R., Antonini G., Bove R., et al. Preliminary clinical study on the treatment of amyotrophic lateral sclerosis with TRH [in Italian]. Clin Ter 119 (1986) 479-481
147. Brooks B.R., Sufit R.L., Montgomery G.K., et al. Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies. Neurol Clin 5 (1987) 143-158
148. Thielen T., Stober T., and Schimrigk K. Therapeutic trial of intrathecal thyrotropin-releasing hormone (TRH) and a TRH-analogue in amyotrophic lateral sclerosis (ALS). Adv Exp Med Biol 209 (1987) 305-308
149. Hawley R.J., Kratz R., Goodman R.R., et al. Treatment of amyotrophic lateral sclerosis with the TRH analog DN-1417. Neurology 37 (1987) 715-717
150. Munsat T.L., Taft J., and Kasdon D. Intrathecal thyrotropin-releasing hormone in amyotrophic lateral sclerosis. Neurol Clin 5 (1987) 159-170
151. Munsat T.L., Taft J., Kasdon D., and Jackson I.M. Prolonged intrathecal infusion of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Ann N Y Acad Sci 531 (1988) 187-193
152. Gueguen B., Puymirat J., Grouselle D., et al. Clinical, electrophysiologic and endocrine effects of the perfusion of high doses of TRH in amyotrophic lateral sclerosis [in French]. Rev Neurol (Paris) 144 (1988) 704-709
153. Klimek A., Szulc-Kuberska J., Czernielewska-Rutkowska I., and Gluszcz-Zielinska A. Treatment of amyotrophic lateral sclerosis with TRH [in Polish]. Neurol Neurochir Pol 22 (1988) 206-210
154. Testa D., Chiodini P.G., Girotti F., and Attanasio R. Amyotrophic lateral sclerosis: thyroid and prolactin hormone changes in thyrotropin-releasing hormone therapy. Ital J Neurol Sci 11 (1990) 601-603
155. Klimek A., Szulc-Kuberska J., and Stepien H. Effect of thyroliberin treatment on the thyrotropin and prolactin levels in patients with amyotrophic lateral sclerosis [in Polish]. Neurol Neurochir Pol 24 (1990) 31-36
156. Munsat T.L., Taft J., Jackson I.M., et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 42 (1992) 1049-1053
157. Patrignani J., Proano J., and Morales M.D. Treatment of amyotrophic lateral sclerosis with daily intrathecal TRH. A year's experience. Pilot study II [in Spanish]. Neurologia 7 (1992) 4-9
158. Current status of thyrotropin-releasing hormone therapy in amyotrophic lateral sclerosis. Committee on Health Care Issues, American Neurological Association. Ann Neurol 22 (1987) 541-543
159. Brooke M.H. Thyrotropin-releasing hormone in ALS. Are the results of clinical studies inconsistent?. Ann N Y Acad Sci 553 (1989) 422-430
160. Miller S.C., and Warnick J.E. Protirelin (thyrotropin-releasing hormone) in amyotrophic lateral sclerosis. The role of androgens. Arch Neurol 46 (1989) 330-335
161. Martinou J.C., Martinou I., and Kato A.C. Cholinergic differentiation factor (CDF/LIF) promotes survival of isolated rat embryonic motoneurons in vitro. Neuron 8 (1992) 737-744
162. Mitsumoto H., Ikeda K., Klinkosz B., et al. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 265 (1994) 1107-1110
163. The ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of sub-cutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46 (1996) 1244-1249
164. Cedarbaum J.M., and Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 152 suppl 1 (1997) S1-S9
165. Miller R.G., Bryan W.W., Dietz M.A., et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 47 (1996) 1329-1331
166. Stambler N., Charatan M., and Cedarbaum J.M. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology 50 (1998) 66-72
167. Penn R.D., Kroin J.S., York M.M., and Cedarbaum J.M. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 40 (1997) 94-99
168. Lewis M.E., Neff N.T., Contreras P.C., et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 124 (1993) 73-88
169. Neff N.T., Prevette D., Houenou L.J., et al. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 24 (1993) 1578-1588
170. Ackerman S.J., Sullivan E.M., Beusterien K.M., et al. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. Pharmacoeconomics 15 (1999) 179-195
171. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2002; CD002064.
172. Henderson C.E., Bloch-Gallego E., Camu W., et al. Motoneuron survival factors: biological roles and therapeutic potential. Neuromusc Disord 3 (1993) 455-458
173. Ikeda K., Klinkosz B., Greene T., et al. Effects of brain-derived neurotrophic factor on motor dys-function in wobbler mouse motor neuron disease. Ann Neurol 37 (1995) 505-511
174. The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52 (1999) 1427-1433
175. Ochs G., Penn R.D., York M., et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) 201-206
176. Fournier J., Steinberg R., Gauthier T., et al. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 55 (1993) 629-641
177. Lechtzin N., Cudkowicz M.E., Clawson L.L., et al. Clinical trial of buspirone in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2 suppl 2 (2001) 162 (abst).
178. Yan W., Wilson C.C., and Haring J.H. 5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. Brain Res Dev Brain Res 98 (1997) 185-190
179. 11C]-WAY100635 PET: A potential in vivo marker for ALS?. Neurology 58 7 suppl 3 (2002) A413
180. Oosthuyse B., Moons L., Storkebaum E., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28 (2001) 131-138
181. Bordet T., Lesbordes J.C., Rouhani S., et al. Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. Hum Mol Genet 10 (2001) 1925-1933
182. Acsadi G., Anguelov R.A., Yang H., et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther 13 (2002) 1047-1059
183. Wang L.J., Lu Y.Y., Muramatsu S., et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 22 (2002) 6920-6928
184. Manabe Y., Nagano I., Gazi M.S., et al. Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Apoptosis 7 (2002) 329-334
185. Drachman D.B., Fishman P.S., Rothstein J.D., et al. Amyotrophic lateral sclerosis. An autoimmune disease?. Adv Neurol 68 (1995) 59-65
186. Engelhardt J.I., Appel S.H., and Killian J.M. Experimental auto-immune motoneuron disease. Ann Neurol 26 (1989) 368-376
187. Engelhardt J.I., and Appel S.H. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 47 (1990) 1210-1216
188. Bradley W.G., Hedlund W., Cooper C., et al. A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology 34 (1984) 1079-1082
189. M1 ganglioside in amyotrophic lateral sclerosis. Neurology 38 (1988) 1457-1461
190. D1a gangliosides in amyotrophic lateral sclerosis. Ann Neurol 25 (1989) 98-102
191. M1 ganglioside. Ann Neurol 24 (1988) 73-78
192. Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology 51 6, suppl 5 (1998) S22-S24
193. Wolfgram F., and Myers L. Amyotrophic lateral sclerosis: effect of serum on anterior horn cells in tissue culture. Science 179 (1973) 579-580
194. Smith R.G., Hamilton S., Hofmann F., et al. Serum antibodies to l-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 327 (1992) 1721-1728
195. Troost D., Van den Oord J.J., and Vianney de Jong J.M. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 16 (1990) 401-410
196. Banati R.B., Gehrmann J., Kellner M., and Holsboer F. Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. Clin Neuropathol 14 (1995) 197-200
197. Kelemen J., Hedlund W., Orlin J.B., et al. Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Arch Neurol 40 (1983) 752-753
198. Mora J.S., Munsat T.L., Kao K.P., et al. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology 36 (1986) 1137-1140
199. Brown Jr. R.H., Hauser S.L., Harrington H., and Weiner H.L. Failure of immunosuppression with a ten-to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch Neurol 43 (1986) 383-384
200. Tan E., Lynn D.J., Amato A.A., et al. Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Arch Neurol 51 (1994) 194-200
201. Appel S.H., Stewart S.S., Appel V., et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 45 (1988) 381-386
202. Werdelin L., Boysen G., Jensen T.S., and Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 82 (1990) 132-134
203. Westarp M.E., Westphal K.P., Kolde G., et al. Dermal, serological and CSF changes in amyotrophic lateral sclerosis with and without intrathecal interferon beta treatment. Int J Clin Pharmacol Ther Toxicol 30 (1992) 81-93
204. Drachman D.B., Chaudhry V., Cornblath D., et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 35 (1994) 142-150
205. Olarte M.R., and Shafer S.Q. Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis. Neurology 35 (1985) 1063-1066
206. Otten A., Vermeulen M., Bossuyt P.M., and Otten A. Intravenous immunoglobulin treatment in neurological diseases. J Neurol Neurosurg Psychiatry 60 (1996) 359-361
207. Meucci N., Nobile-Orazio E., and Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 243 (1996) 117-120
208. Chaudhry V., Corse A.M., Cornblath D.R., et al. Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve 17 (1994) 198-205
209. Taylor B.V., Wright R.A., Harper C.M., and Dyck P.J. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 23 (2000) 900-908
210. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 115 (2001) 4-18
211. M1 antibodies: a double-blind, placebo-controlled study. Neurology 44 3, pt 1 (1994) 429-432
212. Van den Berg L.H., Kerkhoff H., Oey P.L., et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59 (1995) 248-252
213. Federico P., Zochodne D.W., Hahn A.F., et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55 (2000) 1256-1262
214. Leger J.M., Chassande B., Musset L., et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124 pt 1 (2001) 145-153
215. Azulay J.P., Rihet P., Pouget J., et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 62 (1997) 391-394
216. Berg-Vos R.M., Franssen H., Wokke J.H., et al. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 48 (2000) 919-926
217. Nobile-Orazio E., Cappellari A., Meucci N., et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 72 (2002) 761-766
218. Ellis C.M., Leary S., Payan J., et al. Use of human intravenous immunoglobulin in lower motor neuron syndromes. J Neurol Neurosurg Psychiatry 67 (1999) 15-19
219. Umapathi T., Hughes R.A., Nobile-Orazio E., and Leger J.M. Immunosuppressive treatment for multifocal motor neuropathy. Cochrane Database Syst Rev (2002) CD003217.
220. Siddique T., Figlewicz D.A., Pericak-Vance M.A., et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 324 (1991) 1381-1384
221. Rosen D.R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
222. Radunovic A., and Leigh P.N. Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. J Neurol Neurosurg Psychiatry 61 (1996) 565-572
223. Cudkowicz M.E., McKenna-Yasek D., Sapp P.E., et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 41 (1997) 210-221
224. Orrell R.W., Habgood J.J., Malaspina A., et al. Clinical characteristics of SOD1 gene mutations in UK families with ALS. J Neurol Sci 169 (1999) 56-60
225. Gaudette M., Hirano M., and Siddique T. Current status of SOD1 mutations in familial ALS. ALS and other motor neuron disorders 1 (2000) 83-90
226. Gurney M.E., Pu H., Chiu A.Y., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 269 (1995) 149 [published erratum in:].
227. Science 264 (1994) 1772-1775
228. Newbery H.J., and Abbott C.M. Of mice, men and motor neurons. Trends Mol Med 8 (2002) 88-92
229. Noor R., Mittal S., and Iqbal J. Superoxide dismutase. Med Sci Monit 8 (2002) RA210-RA216
230. Reaume A.G., Elliott J.L., Hoffman E.K., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 13 (1996) 43-47
231. Cudkowicz M.E., Warren L., Francis J.W., et al. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Neurology 49 (1997) 213-222
232. Flanagan S.W., Anderson R.D., Ross M.A., and Oberley L.W. Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J Neurochem 81 (2002) 170-177
233. Valentine J.S. Do oxidatively modified proteins cause ALS?. Free Radic Biol Med 33 (2002) 1314-1320
234. Wiedau-Pazos M., Goto J.J., Rabizadeh S., et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 271 (1996) 515-518
235. Estevez A.G., Spear N., Manuel S.M., et al. Role of endogenous nitric oxide and peroxynitrite formation in the survival and death of motor neurons in culture. Prog Brain Res 118 (1998) 269-280
236. Beckman J.S., Estevez A.G., Crow J.P., and Barbeito L. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci 24 11 suppl (2001) S15-S20
237. Stieber A., Gonatas J.O., and Gonatas N.K. Aggregates of mutant protein appear progressively in dendrites, in periaxonal processes of oligodendrocytes, and in neuronal and astrocytic perikarya of mice expressing the SOD1(G93A) mutation of familial amyotrophic lateral sclerosis. J Neurol Sci 177 (2000) 114-123
238. Watanabe M., Dykes-Hoberg M., Culotta V.C., et al. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8 (2001) 933-941
239. Subramaniam J.R., Lyons W.E., Liu J., et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci 5 (2002) 301-307
240. Hottinger A.F., Fine E.G., Gurney M.E., et al. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci 9 (1997) 1548-1551
241. Nagano S., Ogawa Y., Yanagihara T., and Sakoda S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett 265 (1999) 159-162
242. Andreassen O.A., Dedeoglu A., Friedlich A., et al. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp Neurol 168 (2001) 419-424
243. Louwerse E.S., Weverling G.J., Bossuyt P.M., et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 52 (1995) 559-564
244. Cudkowicz M.E., Sexton P.M., Ellis T., et al. The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis. Neurology 52 (1999) 1492-1494
245. Mazzini L., Testa D., Balzarini C., and Mora G. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol 241 (1994) 223-227
246. Szulc-Kuberska J., Klimek A., Stepien H., and Woszczak M. Clinical trial of the treatment of amyotrophic lateral sclerosis with bromocriptine [in Polish]. Neurol Neurochir Pol 24 (1990) 37-41
247. Vyth A., Timmer J.G., Bossuyt P.M., et al. Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. J Neurol Sci 139 suppl (1996) 99-103
248. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
249. 10 as a possible treatment for neurodegenerative diseases. Free Radic Res 36 (2002) 455-460
250. Bowling A.C., Schulz J.B., Brown Jr. R.H., and Beal M.F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61 (1993) 2322-2325
251. Albers D.S., and Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 59 (2000) 133-154
252. Sathasivam S., Ince P.G., and Shaw P.J. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 27 (2001) 257-274
253. Troost D., Aten J., Morsink F., and de Jong J.M. Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons. Bcl-2 expression is increased in unaffected post-central gyrus. Neuropathol Appl Neurobiol 21 (1995) 498-504
254. Martin L.J. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 58 (1999) 459-471
255. Pedersen W.A., Luo H., Kruman I., et al. The prostate apoptosis response-4 protein participates in motor neuron degeneration in amyotrophic lateral sclerosis. FASEB J 14 (2000) 913-924
256. Kostic V., Jackson-Lewis V., de Bilbao F., et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277 (1997) 559-562
257. Pasinelli P., Borchelt D.R., Houseweart M.K., et al. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 95 (1998) 15763-15768
258. Li M., Ona V.O., Guegan C., et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288 (2000) 335-339
259. Sanchez Mejia R.O., Ona V.O., Li M., and Friedlander R.M. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48 (2001) 1393-1399
260. Zhu S., Stavrovskaya I.G., Drozda M., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
261. Kriz J., Nguyen M., and Julien J. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10 (2002) 268
262. Van Den B.L., Tilkin P., Lemmens G., and Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13 (2002) 1067-1070
263. Asanuma M., Nishibayashi-Asanuma S., Miyazaki I., et al. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 76 (2001) 1895-1904
264. Yermakova A., and O'Banion M.K. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 6 (2000) 1755-1776
265. Yasojima K., Tourtellotte W.W., McGeer E.G., and McGeer P.L. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 57 (2001) 952-956
266. Drachman D.B., and Rothstein J.D. Inhibition of cyclooxygenase-2 protects motor neurons in an organ-otypic model of amyotrophic lateral sclerosis. Ann Neurol 48 (2000) 792-795
267. Wagey R., Hu J., Pelech S.L., et al. Modulation of NMDA-mediated excitotoxicity by protein kinase C. J Neurochem 78 (2001) 715-726
268. Noh K.M., Hwang J.Y., Shin H.C., and Koh J.Y. A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiol Dis 7 (2000) 375-383
269. Schwartz Z., Sylvia V.L., Guinee T., et al. Tamoxifen elicits its anti-estrogen effects in growth plate chondrocytes by inhibiting protein kinase C. J Steroid Biochem Mol Biol 80 (2002) 401-410
270. Savas S., Delibas N., Savas C., et al. Pentoxifylline reduces biochemical markers of ischemiareperfusion induced spinal cord injury in rabbits. Spinal Cord 40 (2002) 224-229
271. Liversedge L.A. Glycocyamine and betaine in motor-neurone disease. Lancet (1956) 1136-1138
272. Klivenyi P., Ferrante R.J., Matthews R.T., et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5 (1999) 347-350
273. Ikeda K., Iwasaki Y., and Kinoshita M. Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000) 207-212
274. Earnest C.P., Snell P.G., Rodriguez R., et al. The effect of creatine monohydrate ingestion on anaerobic power indices, muscular strength and body composition. Acta Physiol Scand 153 (1995) 207-209
275. Tarnopolsky M., and Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 52 (1999) 854-857
276. Rosenfeld J., Jackson C.E., Smith J., et al. A pilot trial of ultrapure creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2 suppl 2 (2001) 20
277. Drory V.E., and Gross D. No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 3 (2002) 43-46
278. Denker P.G., and Scheinman L. Treatment of amyotrophic lateral sclerosis with vitamin E (alphatocopherol). JAMA 116 (1941) 1893-1895
279. Desnuelle C., Dib M., Garrel C., and Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzoletocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2 (2001) 9-18
280. Esposito E., Rotilio D., Di M., et al. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging 23 (2002) 719
281. Butterfield D.A., Castegna A., Drake J., et al. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr Neurosci 5 (2002) 229-239
282. Apostolski S., Marinkovic Z., Nikolic A., et al. Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. J Environ Pathol Toxicol Oncol 17 (1998) 325-329
283. Norris F.H., Denys E.H., and Fallat R.J. Trial of octacosanol in amyotrophic lateral sclerosis. Neurology 36 (1986) 1263-1264
284. Kaji R., Kodama M., Imamura A., et al. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve 21 (1998) 1775-1778
285. Norris F.H. Ceftriaxone in amyotrophic lateral sclerosis. Arch Neurol 51 (1994) 447
286. Couratier P., Vallat J.M., Merle L., et al. Report of six sporadic cases of ALS patients receiving ceftriaxone. Therapie 49 (1994) 146
287. Johnson R.T. Virological studies of amyotrophic lateral sclerosis: an overview. UCLA Forum Med Sci (1976) 173-180
288. Smith R.A., and Norris F.H. Antiviral therapy. Adv Exp Med Biol 209 (1987) 297-304
289. Jubelt B. Motor neuron diseases and viruses: poliovirus, retroviruses, and lymphomas. Curr Opin Neurol Neurosurg 5 (1992) 655-658
290. Karpati G., and Dalakas M.C. Viral hide-and-seek in sporadic ALS: a new challenge. Neurology 54 (2000) 6-7
291. Jubelt B., and Berger J.R. Does viral disease underlie ALS? Lessons from the AIDS pandemic. Neurology 57 (2001) 945-946
292. Viola M.V., Myers J.C., Gann K.L., et al. Failure to detect poliovirus genetic information in amyotrophic lateral sclerosis. Ann Neurol 5 (1979) 402-403
293. Miller J.R., Guntaka R.V., and Myers J.C. Amyotrophic lateral sclerosis: search for poliovirus by nucleic acid hybridization. Neurology 30 (1980) 884-886
294. Kohne D.E., Gibbs C.J., White L., et al. Virus detection by nucleic acid hybridization: examination of normal and ALS tissues for the presence of poliovirus. J Gen Virol 56 pt 2 (1981) 223-233
295. Brahic M., Smith R.A., Gibbs Jr. C.J., et al. Detection of picornavirus sequences in nervous tissue of amyotrophic lateral sclerosis and control patients. Ann Neurol 18 (1985) 337-343
296. Bartfeld H., Dham C., Donnenfeld H., et al. Enteroviral-related antigen in circulating immune complexes of amyotrophic lateral sclerosis patients. Intervirology 30 (1989) 202-212
297. Swanson N.R., Fox S.A., and Mastaglia F.L. Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Neuromusc Disord 5 (1995) 457-465
298. Berger M.M., Kopp N., Vital C., et al. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 54 (2000) 20-25
299. Andrews W.D., Tuke P.W., Al Chalabi A., et al. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol 61 (2000) 527-532
300. Pamphlett R. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 55 (2000) 1420-1421
301. Walker M.P., Schlaberg R., Hays A.P., et al. Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients. Ann Neurol 49 (2001) 249-253
302. Giraud P., Beaulieux F., Ono S., et al. Detection of enteroviral sequences from frozen spinal cord samples of Japanese ALS patients. Neurology 56 (2001) 1777-1778
303. Sola P., Bedin R., Casoni F., et al. New insights into the viral theory of amyotrophic lateral sclerosis: study on the possible role of Kaposi's sarcoma-associated virus/human herpesvirus 8. Eur Neurol 47 (2002) 108-112
304. Fareed G.C., and Tyler H.R. The use of isoprinosine in patients with amyotrophic lateral sclerosis. Neurology 21 (1971) 937-940
305. Munsat T.L., Easterday C.S., Levy S., et al. Amantadine and guanidine are ineffective in ALS. Neurology 31 (1981) 1054-1055
306. Olson W.H., Simons J.A., and Halaas G.W. Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study. Neurology 28 (1978) 1293-1295
307. Nevsimal O., Pekarek J., Koubek K., et al. Low-molecular transfer factor and its use in the treatment of amyotrophic lateral sclerosis [in Czech]. Cesk Neurol Neurochir 54 (1991) 220-222
308. Moulignier A., Moulonguet A., Pialoux G., and Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology 57 (2001) 995-1001
309. MacGowan D.J., Scelsa S.N., and Waldron M. An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy. Neurology 57 (2001) 1094-1097
310. Ansevin C.F. Treatment of ALS with pleconaril. Neurology 56 (2001) 691-692
311. Mendell J.R., Chase T.N., and Engel W.K. Amyotrophic lateral sclerosis: metabolism of central monoamines and treatment with l-dopa. Trans Am Neurol Assoc 96 (1971) 284-286
312. Handa I., Matsushita N., Ihashi K., et al. A clinical trial of therapeutic electrical stimulation for amyotrophic lateral sclerosis. Tohoku J Exp Med 175 (1995) 123-134
313. Norris Jr. F.H., Sachais B., and Carey M. Trial of baclofen in amyotrophic lateral sclerosis. Arch Neurol 36 (1979) 715-716
314. Aquilonius S.M., Askmark H., Eckernas S.A., et al. Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine. Acta Neurol Scand 73 (1986) 628-632
315. Aisen M.L., Sevilla D., Edelstein L., and Blass J. A double-blind placebo-controlled study of 3,4-diaminopyridine in amyotrophic lateral sclerosis patients on a rehabilitation unit. J Neurol Sci 138 (1996) 93-96
316. Askmark H., Aquilonius S.M., Gillberg P.G., et al. Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 82 (1990) 253-258
317. Orrell R.W., and Figlewicz D.A. Clinical implications of the genetics of ALS and other motor neuron diseases. Neurology 57 (2001) 9-17
318. Shaw P.J. Genetic inroads in familial ALS. Nat Genet 29 (2001) 103-104
319. Radunovic A., and Leigh P.N. ALSO Database: database of SOD1 (and other) gene mutations in ALS on the Internet. European FALS Group and ALSOD Consortium. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (1999) 45-49
320. Hadano S., Hand C.K., Osuga H., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 29 (2001) 166-173
321. Yang Y., Hentati A., Deng H.X., et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29 (2001) 160-165
322. Leavitt B. Hereditary motor neuron disease caused by mutations in the ALS2 gene: "The long and the short of it.". Clin Genet 62 (2002) 265
323. A1-Chalabi A., Hansen V.K., Simpson C.L., et al. Variants in the ALS2 gene are not associated with sporadic amyotrophic lateral sclerosis. Neurogenetics (2003) (in press).
324. Hentati A., Ouahchi K., Pericak-Vance M.A., et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics 2 (1998) 55-60
325. Chance P.F., Rabin B.A., Ryan S.G., et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 62 (1998) 633-640
326. Hosler B.A., Siddique T., Sapp P.C., et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 284 (2000) 1664-1669
327. Hand C.K., Khoris J., Salachas F., et al. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 70 (2002) 251-256
328. Ruddy D.M., Parton M.J., Al-Chalabi, et al. Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am J Hum Genet (2003) (in press).
329. Hayward C., Colville S., Swingler R.J., and Brock D.J. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 52 (1999) 1899-1901
330. Carpenter S. Proximal axonal enlargement in motor neuron disease. Neurology 18 (1968) 841-851
331. Hirano A., Donnenfeld H., Sasaki S., and Nakano I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 43 (1984) 461-470
332. Hirano A., Nakano I., Kurland L.T., et al. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 43 (1984) 471-480
333. Xu Z., Cork L.C., Griffin J.W., and Cleveland D.W. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 73 (1993) 23-33
334. Williamson T.L., and Cleveland D.W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 2 (1999) 50-56
335. Cote F., Collard J.F., and Julien J.P. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 73 (1993) 35-46
336. Figlewicz D.A., Krizus A., Martinoli M.G., et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 3 (1994) 1757-1761
337. Al-Chalabi A., Andersen P.M., Nilsson P., et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 8 (1999) 157-164
338. Williamson T.L., Bruijn L.I., Zhu Q., Anderson K.L., et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 95 (1998) 9631-9636
339. Couillard-Despres S., Zhu Q., Wong P.C., et al. Protective effect of neurofilament heavy gene over-expression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA 95 (1998) 9626-9630
340. Kong J., and Xu Z. Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis. Neurosci Lett 281 (2000) 72-74
341. Beaulieu J.M., Nguyen M.D., and Julien J.P. Late onset death of motor neurons in mice overexpressing wild-type peripherin. J Cell Biol 147 (1999) 531-544
342. Menzies F.M., Cookson M.R., Taylor R.W., et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 125 pt 7 (2002) 1522-1533
343. Menzies F.M., Ince P.G., and Shaw P.J. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 40 (2002) 543-551
344. Vielhaber S., Kunz D., Winkler K., et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 123 pt 7 (2000) 1339-1348
345. Dhaliwal G.K., and Grewal R.P. Mitochondrial DNA deletion mutation levels are elevated in ALS brains. Neuroreport 11 (2000) 2507-2509
346. Talbot K., and Davies K.E. Spinal muscular atrophy. Semin Neurol 21 (2001) 189-197
347. Lefebvre S., Burglen L., Reboullet S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995) 155-165
348. Roy N., Mahadevan M.S., McLean M., et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80 (1995) 167-178
349. Nicole S., Diaz C.C., Frugier T., and Melki J. Spinal muscular atrophy: recent advances and future prospects. Muscle Nerve 26 (2002) 4-13
350. Talbot K., Ponting C.P., Theodosiou A.M., et al. Missense mutation clustering in the survival motor neuron gene: a role for a conserved tyrosine and glycine rich region of the protein in RNA metabolism?. Hum Mol Genet 6 (1997) 497-500
351. Talbot K., Miguel-Aliaga I., Mohaghegh P., et al. Characterization of a gene encoding survival motor neuron (SMN)-related protein, a constituent of the spliceosome complex. Hum Mol Genet 7 (1998) 2149-2156
352. Iwahashi H., Eguchi Y., Yasuhara N., et al. Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy. Nature 390 (1997) 413-417
353. Orrell R.W., Habgood J.J., de Belleroche J.S., and Lane R.J. The relationship of spinal muscular atrophy to motor neuron disease: investigation of SMN and NAIP gene deletions in sporadic and familial ALS. J Neurol Sci 145 (1997) 55-61
354. Parboosingh J.S., Meininger V., McKenna-Yasek D., et al. Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis. Arch Neurol 56 (1999) 710-712
355. Veldink J.H., Van den Berg L.H., Cobben J.M., et al. Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology 56 (2001) 749-752
356. Fink J.K. Progressive spastic paraparesis: hereditary spastic paraplegia and its relation to primary and amyotrophic lateral sclerosis. Semin Neurol 21 (2001) 199-207
357. Hazan J., Fonknechten N., Mavel D., et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet 23 (1999) 296-303
358. Saugier-Veber P., Munnich A., Bonneau D., et al. X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet 6 (1994) 257-262
359. Saugier-Veber P., Martin C., Le Meur N., et al. Identification of novel L1CAM mutations using fluorescence-assisted mismatch analysis. Hum Mutat 12 (1998) 259-266
360. Casari G., De Fusco M., Ciarmatori S., et al. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 93 (1998) 973-983
361. Casari G., and Rugarli E. Molecular basis of inherited spastic paraplegias. Curr Opin Genet Dev 11 (2001) 336-342
362. Schwartz G.A., and Lui C.N. Hereditary (familial) spastic paraplegia: further clinical and pathological observations. AMA Arch Neurol Psychiatry 75 (1956) 144-162
363. Smith B.N., and Shaw C.E. Screening of FALS patients with wild-type SOD1 for mutations in the SPG4 gene that is linked to autosomal dominant hereditary spastic paraplegia. Amyotroph Lateral Scler Other Motor Neuron Disord 3 suppl 2 (2002) 64
364. Kennedy W.R., Alter M., and Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology 18 (1968) 671-680
365. La Spada A.R., Wilson E.M., Lubahn D.B., et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352 (1991) 77-79
366. Yamashita S., Mita S., Kato S., et al. Effect on motor neuron survival in mutant SOD1 (G93A) transgenic mice by Bcl-2 expression using retrograde axonal transport of adenoviral vectors. Neurosci Lett 328 (2002) 289-293
367. Martin-Rendon E., Azzouz M., and Mazarakis N.D. Lentiviral vectors for the treatment of neurodegenerative diseases. Curr Opin Mol Ther 3 (2001) 476-481
368. Holden C. Neuroscience. Versatile cells against intractable diseases. Science 297 (2002) 500-502
369. Johansson C.B., Svensson M., Wallstedt L., et al. Neural stem cells in the adult human brain. Exp Cell Res 253 (1999) 733-736
370. Magavi S.S., and Macklis J.D. Manipulation of neural precursors in situ: induction of neurogenesis in the neocortex of adult mice. Neuropsychopharmacology 25 (2001) 816-835
371. Song H.J., Stevens C.F., and Gage F.H. Neural stem cells from adult hippocampus develop essential properties of functional CNS neurons. Nat Neurosci 5 (2002) 438-445
372. Gritti A., Bonfanti L., Doetsch F., et al. Multipotent neural stem cells reside into the rostral extension and olfactory bulb of adult rodents. J Neurosci 22 (2002) 437-445
373. Wichterle H., Lieberam I., Porter J.A., and Jessell T.M. Directed differentiation of embryonic stem cells into motor neurons. Cell 110 (2002) 385-397
374. Maragakis N.J., et al. Transplanted neural stem cells are capable of engraftment and differentiation in transgenic mutant SOD1 mice. Soc Neurosci Abstracts 26 (2000) 668 3.
375. Garbuzova-Davis S., Willing A.E., Milliken M., et al. Positive effect of transplantation of hNT neurons (NTera 2/D1 cell-line) in a model of familial amyotrophic lateral sclerosis. Exp Neurol 174 (2002) 169-180
376. Vastag B. Stem cells step closer to the clinic: paralysis partially reversed in rats with ALS-like disease. JAMA 285 (2001) 1691-1693